- Home
- LANV vs CERS Comparison
LANV vs CERS Comparison
Compare LANV & CERS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LANV
- CERS
- Stock Information
- Founded
- LANV 2015
- CERS 1991
- Country
- LANV China
- CERS United States
- Employees
- LANV N/A
- CERS N/A
- Industry
- LANV Blank Checks
- CERS EDP Services
- Sector
- LANV Finance
- CERS Technology
- Exchange
- LANV Nasdaq
- CERS Nasdaq
- Market Cap
- LANV 244.4M
- CERS 276.0M
- IPO Year
- LANV N/A
- CERS 1997
- Fundamental
- Price
- LANV $2.01
- CERS $1.69
- Analyst Decision
- LANV
- CERS Buy
- Analyst Count
- LANV 0
- CERS 1
- Target Price
- LANV N/A
- CERS $4.00
- AVG Volume (30 Days)
- LANV 38.9K
- CERS 1.3M
- Earning Date
- LANV 08-29-2025
- CERS 11-06-2025
- Dividend Yield
- LANV N/A
- CERS N/A
- EPS Growth
- LANV N/A
- CERS N/A
- EPS
- LANV N/A
- CERS N/A
- Revenue
- LANV $341,783,911.00
- CERS $199,191,000.00
- Revenue This Year
- LANV N/A
- CERS $19.07
- Revenue Next Year
- LANV $6.90
- CERS $12.03
- P/E Ratio
- LANV N/A
- CERS N/A
- Revenue Growth
- LANV N/A
- CERS 13.03
- 52 Week Low
- LANV $1.32
- CERS $1.12
- 52 Week High
- LANV $2.69
- CERS $2.24
- Technical
- Relative Strength Index (RSI)
- LANV 49.38
- CERS 59.50
- Support Level
- LANV $1.83
- CERS $1.47
- Resistance Level
- LANV $2.18
- CERS $1.78
- Average True Range (ATR)
- LANV 0.16
- CERS 0.13
- MACD
- LANV -0.00
- CERS 0.01
- Stochastic Oscillator
- LANV 56.74
- CERS 80.00
About LANV Lanvin Group Holdings Limited
Lanvin Group Holdings Ltd engages in offering products ranging from apparel to leather goods, footwear, and accessories. The firm is operating mainly 5 portfolio brands, namely Lanvin, Wolford, Sergio Rossi, St. John, and Caruso. It derives the majority of its revenue from the Wolford segment.
About CERS Cerus Corporation
Cerus Corp is a biomedical products company focused on the field of blood transfusion safety. The INTERCEPT Blood System is designed to reduce the risk of transfusion-transmitted infections by inactivating a broad range of pathogens such as viruses, bacteria, and parasites. The company sells its INTERCEPT platelet and plasma systems in the United States of America, Europe, the Commonwealth of Independent States countries, the Middle East, and selected countries in other regions around the world. The firm continues to operate in only one segment: Blood safety and generates revenue from the same.